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Abstract
Mesenchymal stromal cells from the human amniotic membrane (i.e., human amniotic mesenchymal stromal cells [hAMSCs])
of term placenta are increasingly attracting attention for their applications in regenerative medicine. Osteochondral defects
represent a major clinical problem with lifelong chronic pain and compromised quality of life. Great promise for osteochondral
regeneration is held in hydrogel-based constructs that have a flexible composition and mimic the physiological structure of
cartilage. Cell loading within a hydrogel represents an advantage for regenerative purposes, but the encapsulation steps can
modify cell properties. As pectin gels have also been explored as cell vehicles on 3D scaffolds, the aim of this study was to
explore the possibility to include hAMSCs in pectin gel. Immobilization of hAMSCs into pectin gels could expand their
application in cell-based bioengineering strategies. hAMSCs were analyzed for their viability and recovery from the pectin gel
and for their ability to differentiate toward the osteogenic lineage and to maintain their immunological characteristics. When
treated with a purposely designed pectin/hydroxyapatite gel biocomposite, hAMSCs retained their ability to differentiate
toward the osteogenic lineage, did not induce an immune response, and retained their ability to reduce T cell proliferation.
Taken together, these results suggest that hAMSCs could be used in combination to pectin gels for the study of novel
osteochondral regeneration strategies.
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Introduction
Osteochondral defects resulting from congenital defects,
pathological disorders, and/or traumatic injury represent a
major clinical problemwith lifelong chronic pain and compro-
mised quality of life1,2. Due to its poor regenerative capacity,
stratified architecture, and disparate biochemical properties,
the challenge remains to replicate robust integration of carti-
lage and subchondral bone and the complex stratified tissue3,4.
Bioengineered scaffolds are being widely investigated for
osteochondral regeneration strategies. Various scaffolds,
such as porous sponges5–7,meshes, and hydrogels8, have been
prepared from biodegradable synthetic and natural polymers
for tissue engineering applications9 and have been shown to
influence cell functions and improve cartilage, osteochon-
dral, and bone regeneration. Among the different properties
of scaffolds, a flexible structure mimicking the physiological
structure of cartilage is essential. In this perspective, great
promise for osteochondral regenerative medicine is entrusted
in hydrogel-based structures8,10,11 that can be obtained by the
use of natural polymers. Among them, pectins, a family of
polysaccharides found in the primary cell walls of plant cells,
are commonly used in drug delivery and wound-healing
applications12–15. Embedding cells in a hydrogel has several
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advantages. First, considering cell delivery for regenerative
purposes, the presence of a gel has the advantage of confining
cells in a specific site and fitting/adapting them to the specific
defect, while at the same time insulating and protecting the
cells from the surrounding microenvironment16. Second, it
can also allow processing techniques which are commonly
used to obtain graded scaffolds, such as preparing cell-loaded
hydrogel sheets, impregnating porous structures with the cell-
loaded gel, and production of multilayered scaffolds17.
Current developments in tissue engineering strategies for
articular cartilage regeneration focus on the design of sup-
portive 3-dimensional (3-D) scaffolds and their use in com-
bination with cells from different sources18,19. In this
scenario, scaffolds allow delivery and retention of the cells
at the defect site. Mesenchymal stromal cells (MSCs) have
been widely investigated in tissue engineering strategies for
articular cartilage regeneration. MSCs possess extensive
proliferation potential and proven capability to differentiate
along the osteochondral pathway20. In addition to prolifera-
tion and multilineage differentiation potential, MSCs pos-
sess immune-modulatory and anti-inflammatory functions,
which may enhance their regenerative power20.
While MSCs from bone marrow are widely used, more
recently, MSCs from human term placenta have gained atten-
tion due to their unique properties. After birth, the placenta is
usually discarded as nothing more than biological waste, and
thus placental tissue is easily accessible in a noninvasive way.
Furthermore, compared to MSCs from other sources such as
bone marrow and adipose tissue, high cell recovery is possible
from placental tissues. Human placenta is composed of a fetal
part, including the amnion, chorion, umbilical cord, and a
maternal part, termed decidua. Within these components, dif-
ferent cell subpopulations with mesenchymal characteristics
may be isolated, and as established by the consensus of the
First InternationalWorkshop on Placenta-Derived StemCells,
they are referred to human amniotic mesenchymal stromal
cells (hAMSCs) and human chorion mesenchymal stromal
cells21. Nowadays, it has been widely demonstrated that
some cells from the human placenta possess some stem/
progenitor cell potential which is thought, at least in part,
to be due to the early origin of placental tissues during embry-
ogenesis and prior to gastrulation21,22. In addition, placental
MSCs, and more specifically MSCs from the amniotic
membrane, possess intrinsic immune-modulatory properties
which do not require licensing with inflammatory stimuli as
suggested with MSCs from bone marrow23.
The aim of this study is to evaluate hAMSC in vitro prop-
erties after pectin gel treatment to establish whether hAMSCs
could be ideal candidates for cell-based bioengineering stra-
tegies using pectin gels as cell vehicles on 3-D scaffolds. First,
we investigated hAMSC recovery and cell viability after load-
ing into a pectin gel. Then, we investigated whether hAMSCs
retained their unique functional properties, such as the inabil-
ity to mount an immune response, ability to decrease the
proliferation of activated peripheral blood mononuclear cells
(PBMCs), and to differentiate toward the osteogenic lineage.
We conclude that pectin gel treatment does not alter hAMSCs
and does not influence their immunological properties nor
osteogenic differentiation, suggesting that hAMSCs could
be used in combination with pectin gels obtained in the




All samples used in this study were obtained after informed
consent from donors. For human term placenta and peripheral
blood samples, written informed consent to collect placenta
and isolate human amniotic-derived cells was obtained from
each single donor according to the guidelines of the Ethics
Committee (Comitato Etico Provinciale) of the province of
Brescia.
Human MSC Isolation, Growth, and Cryopreservation
Human termplacentas (n¼ 12) were processedwithin approx-
imately 8 h after birth. The amnion was manually separated
from the chorion and washed extensively in saline sodium
chloride 0.9%with 100 U/mL penicillin and 100 mg/mL strep-
tomycin (herein referred to as P/S, both from Sigma-Aldrich,
St. Louis, MO, USA) and 2.5 mg/mL amphotericin B (Sigma-
Aldrich). Afterward, the amnion was cut into small fragments
(*3  3 cm2) which were decontaminated by a brief incuba-
tion in saline sodium chloride 0.9%þ 2.5%Betadine 0.25%
Iodopovidone (Betadine-Esojod 10%, Ecolab-Esoform,
Venice, Italy) and 3 min in phosphate-buffered saline (PBS;
Sigma-Aldrich) containing 500 U/mL penicillin, 500 mg/mL
streptomycin, 12.5 mg/mL amphotericin B, and 1.87 mg/mL
Cefamezin (Teva, Italy). The amnion fragments were then
incubated for 9min at 37 C inHBSS (Sigma-Aldrich) contain-
ing 2.5 U/mL dispase (VWR, Milan, Italy). After a 3 to 5 min
resting period at room temperature in Roswell Park Memorial
Institute (RPMI) 1640medium (Sigma-Aldrich) supplemented
with 10% heat-inactivated fetal bovine serum (FBS, Sigma-
Aldrich), 2 mM L-glutamine (Sigma-Aldrich), and P/S, the
fragmentsweredigestedwith0.94mg/mLcollagenase (Roche,
Mannheim, Germany) and 0.01mg/mLDNase (Roche) for 2.5
h at 37 C. Amnion fragments were removed, and mobilized
cells were passed through a 100-mm strainer (BD Falcon, Bed-
ford, MA, USA) and collected by centrifugation at 300 g for
10 min. The cell suspension was filtered a second time with a
70-mm strainer (BD Falcon). Cells were frozen in 90% heat-
inactivated FBS and 10% dimethyl sulfoxide (DMSO) (Sigma-
Aldrich) in liquid nitrogen until use.
To obtain hAMSCs at passage 1, freshly isolated or
thawed cells were plated in flasks (Corning Inc, Corning,
NY, USA) at a density of 10,000 cells/cm2 in CHANG
Medium C supplemented with 2 mM L-glutamine and P/S.
Upon reaching subconfluency, adherent cells were washed
in PBS, detached with 0.25% trypsin (Sigma-Aldrich), and
then cultured for subsequent experiments.
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Cell viability and recovery were analyzed using the try-
pan blue exclusion assay.
hAMSC Loading into the Pectin Gel
Low-methoxyl pectin (CU701, kindly provided by Herb-
streith & Fox, Nuremberg, Germany) was dissolved over-
night in a sterile NaCl (10.8 mg/mL; Sigma-Aldrich) 
NaHCO3 (2.52 mg/mL; Sigma-Aldrich) solution at a final
concentration of 22.5 mg/mL. Calcium phosphate (CaP;
kindly provided by Eurocoating SpA [Italy], hydroxyapatite
granules, in the range 20 to 40 mm) was suspended in water
to obtain a final concentration of 23 mM.
CaP suspension (0.4mL) wasmixed with pectin solution (2
mL) and 5 105 hAMSCs were added by resuspension in 0.4
mLof completemedium (DMEM [Sigma]þ 20% FBS), using
a dual-syringe system. Afterward, 0.4 mL aliquots of the
hAMSC–pectin gel suspension were plated in 24-well plates
(Corning) and incubated for 30 s with 0.1 mL of 2% w/v of
calcium gluconate (Sigma). Complete medium (0.5 mL) was
added to each well and the plates were incubated at 37 C and
5% CO2 for different time points (1, 3, 24, 48, 72, and 168 h).
As controls, hAMSCs were mixed and plated in complete cul-
ture medium (Dulbecco’s modified Eagle’s medium (DMEM)
þ 20% FBS) using a dual-syringe system or, to mimic the gel
consistency of pectin, in Matrigel™ Basement Membrane
Matrix (BD Biosciences). At the end of incubation, 1 mL of
PBS þ 25% ethylenediaminetetraacetic acid (EDTA) 0.5 M
was added to each well to dissolve the pectin gel. Prior to
immunological and differentiation assays, CaP was depleted
using density gradient centrifugation (Histopaque; Sigma-
Aldrich) due to its interference in these assays.
Osteogenic Differentiation
For the treatment conditions described above, hAMSCs (1
104/cm2) were seeded in DMEM þ 20% FBS þ P/S þ
L-glutamine. Three days later, culture medium was substi-
tuted with Stempro Osteo/Chondrocyte Diff Basal Medium
with osteogenic supplement (Life Technologies). For con-
trols, culture medium was substituted with fresh medium.
Culture medium was changed twice a week.
Osteogenic differentiation was assessed after 14 d and cal-
cium deposits were visualized using the Alizarin Red (Sigma-
Aldrich) and Von Kossa (Bio Optica) stainings. Cells were
fixed in 10% formalin and 2%Alizarin Red pH 4.2 was added,
left for 25 min, and afterward cells were washed with distilled
water. Alternatively, cells were fixed in 10% formalin and 5%
silver nitrate (Sigma-Aldrich) was added for 1 h under ultra-
violet light, washedwith water, and incubatedwith 5% sodium
thiosulfate (Sigma-Aldrich) for 5 min and washed once more.
Immunological Studies
The ability of hAMSCs to either induce a T-cell response or
inhibit the proliferation of PBMCs activated with anti-CD3
was performed as previously described24. PBMCs were
obtained from heparinized whole blood samples or buffy
coats from healthy subjects using density gradient centrifu-
gation (Histopaque; Sigma-Aldrich).
PBMCs (1  105/well in a 96-well plate) were cultured
with hAMSCs (PBMC:hAMSC ratios 1:1, 1:0.5, 1:0.1,
1:0.02, and 1:0.004) or were stimulatedwith 125 ng/mL (final
concentration) a-CD3 (Orthoclone OKT3, Janssen-Cilag) in
the presence of hAMSCs (PBMC:hAMSC ratios 1:1, 1:0.5,
and 1:0.1). All conditions were performed in triplicate in
DMEM (Sigma-Aldrich) supplemented with 20% heat-
inactivated FBS, 2 mM L-glutamine, and P/S. After 3 d of
culture, lymphocyte proliferation was assessed by adding
0.67 mCi of [3H]-thymidine (INCBiomedicals) per well. Six-
teen to 18 h after the addition of thymidine, cell cultures were
harvested with a FilterMate Harvester (PerkinElmer), and
thymidine incorporation was measured using a microplate
scintillation and luminescence counter (Top Count NXT;
PerkinElmer).
Lymphocyte proliferation was examined in the presence of
irradiated (3,000 cGy) hAMSCs (0.1  105/well, 0.5  105/
well, and 1  105/well) in contact with activated PBMCs.
Statistical Analysis
All data are expressed as mean+ standard error of the mean
(SEM). All statistical analyses were performed using Graph-
Pad Prism version 6.00 for Windows (Graph-Pad Software,
San Diego, CA, USA). Analysis of cell recovery and viabi-
lity was performed using an analysis of variance (ANOVA)
or unpaired t-test. Comparison of counts per minute values
between hAMSCs and PBMC activated with a-CD3 was
performed using an ANOVA.
Results
hAMSC Recovery and Viability After Loading into Pectin
Gel
We investigated whether loading hAMSCs into pectin gel
(pectin and CaP) altered cell recovery and viability. First, we
cultured hAMSCs in pectin gel or in complete culture
medium (DMEM þ 20%FBS) for different time intervals,
from 1 h up to 7 d. As an additional control to mimic the gel
consistency of pectin, hAMSCs were also cultured in
Matrigel™ basement membrane matrix. After incubation in
EDTA to remove pectin gel, residual fragments of the gel
were observed and the concentration of EDTA was progres-
sively increased up to 5 M during the development of the cell
recovery protocols, indicating a strong interaction of the
pectin chains with Caþþ cross-linker. Sodium citrate was
not effective for the dissolution of the gels.
We detected a 50% drop in cell recovery after 1 h of
incubation within the pectin gel; this did not decrease further
and remained constant for up to 7 d after incubation
(Fig. 1A). In addition, no effects on hAMSC viability were
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observed for up to 24 h after incubation within pectin gel
when compared to untreated hAMSCs at time 0 (T0;
Fig. 1B). There was a small, but significant, decrease in
hAMSC viability only 48 and 72 h after incubation in pectin
gel, but viability began to increase again 7 d after incubation
within pectin gel when compared to untreated hAMSCs at
T0 (Fig. 1B). Cell viability decreased from 83% at T0
(before loading into pectin gel) to 58% after a 7-d treatment
with pectin gel. Cell recovery was similar between all the
considered time points, thus subsequent studies were per-
formed using a 3-h treatment within the pectin gel.
The recovery and viability of hAMSCs cultured in com-
plete culture medium decreased continuously up to 24 h after
culture, likely due to the stress induced by the dual-syringe
system used to mix the cell suspension, but then slowly
began to increase until the end of the analysis (168 h;
Fig. 1A). hAMSC recovery after treatment with Matrigel
was similar to those after treatment with pectin gel (Fig. 1B).
Clinical use of MSCs often requires cell expansion to
obtain a high number of cells for injection into patients.
Thus, we analyzed the effects of immobilization within pec-
tin gel on culture-expanded hAMSCs. As shown in Fig. 1,
pectin gel did not alter the recovery (Fig. 1C) or viability
(Fig. 1D) of hAMSCs at passage 1, thus subsequent experi-
ments were performed using hAMSCs at passage 1.
Immunological Properties and Osteogenic
Differentiation Capabilities of hAMSCs After Loading
into Pectin Gel
Since the low immunogenicity and immunomodulatory
properties of hAMSCs are well-documented24–32 and have
been linked to their use in allogeneic settings and therapeutic
effects in preclinical models of inflammatory-based dis-
eases33, we next sought to investigate whether loading into
pectin gel altered these properties. Pectin gel loading
had no effect on the inability of hAMSCs to induce a T cell
proliferative response (Fig. 2A). Also, as shown in Fig. 2B,
hAMSCs and pectin gel-loaded hAMSCs were both able to
significantly inhibit anti-CD3-activated PBMCs when cul-
tured in contact with each other at the 2 highest hAMSC
concentrations used (activated PBMC:hAMSC ratios of
1:0.5 and 1:1). No significant differences were observed in
the ability to inhibit T cell proliferation between hAMSCs
alone and hAMSCs loaded into pectin gel (Fig. 2B).
We also investigated the differentiation ability of
hAMSCs toward the osteogenic lineage after loading within
pectin gel using Alizarin Red and von Kossa stainings
(Fig. 2C). There were no qualitative differences in the degree
of differentiation between untreated hAMSCs and hAMSCs
loaded into the gel.
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Fig. 1. Human amniotic mesenchymal stromal cell (hAMSC) recovery and viability after loading into pectin gel. Panels (A) and (B) show
hAMSC recovery (percentage vs. time 0 set to 100%) and viability, respectively, at passage 0 analyzed at different time points (T) after loading
into pectin gel (circles, bold line) or after culture in complete medium (DMEMþ 20% fetal bovine serum; squares) or in Matrigel™ Basement
Membrane Matrix (triangles). For (A) and (B), data are expressed as mean+ standard error mean of3 different hAMSC donors. Since no
significant alterations were observed starting from 1 h up to 168 h after incubation with pectin, the time point of 3 h was chosen for the
analyses shown in panels (C) and (D); bars represent mean values. A P value of less than 0.05 was considered statistically significant: *P < 0.05,
**P < 0.01, and ***P < 0.001 versus pectin gel.
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Discussion and Conclusions
This is the first study investigating MSCs from the amniotic
membrane of human term placenta as potential cell candi-
dates in 3-D scaffolds using pectin gel cell carrier. MSCs
from the amniotic membrane present unique characteristics;
they are easily accessible in a noninvasive way, and they
possess intrinsic immune-modulatory properties which do
not require licensing with inflammatory stimuli as suggested
with MSCs from bone marrow34. Thus, amniotic membrane
MSCs could represent attractive candidates in tissue engi-
neering strategies for ostechondral defect regeneration in
combination to 3-D scaffolds.
Cell immobilization, and ultimately the limited exposure to
cell culture media, may alter the properties of cells such as the
cell viability. Recently, pectin gels have shown interesting
properties toward bone regeneration15 andpromotionofminer-
alization35. Pectin microcapsules15 and injectable gels36 mod-
ified with arginylglycylaspartic acid (RGD)-containing
peptides have demonstrated their ability to maintain viability
of cells embedded within the gels, both in vitro and in vivo36.
The properties of the pectin gels can be controlled by finely
tuning the cross-linking process37. Among pectin gels, CaPs/
pectin gels have been previously produced by exploiting the
double effect of cross-linker and filler to produce biocomposite
gels38,39 or by incorporating nano-hydroxyapatite to support
osteoblast growth40. The addition of pectin in bone cements,
based on CaPs, has been shown to improve the adhesion and
proliferation of human adipose tissue-derived stem cells41.
Herein, we sought to investigate whether hAMSCs and
CaP/pectin gel that includes CaP as a biomimetic compound
could be compatible partners in cell-based bioengineering
strategies. Thus, the focus of this study was to define
whether pectin gel did not alter viability and characteristics
of amniotic cells.
When hAMSCs were encapsulated in the pectin gel, cell
recovery dropped by 50% after 1 h of incubation, and the
recovery remained stable (50%) at all considered time points.
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Fig. 2. Human amniotic mesenchymal stromal cells’ (hAMSCs) functional properties after incubation with pectin gel. (A) Proliferation of
peripheral blood mononuclear cells (PBMCs) alone, in presence of hAMSCs, at passage 1, or in presence of hAMSCs passage 1 (p1)
recovered from pectin gel dissolution. Data are expressed as mean + standard error mean (SEM) of 4 different hAMSC donors. (B)
Proliferation of PBMCs activated with anti-CD3 in presence of hAMSCs at passage 1 or in presence of hAMSCs (p1) recovered from pectin
gel dissolution. Data are expressed as mean+ SEM of6 different hAMSC donors. Comparison of counts per minute (cpm) values between
untreated and treatment hAMSCs and PBMCs activated with anti-CD3 was performed using a t-test. A P value of less than 0.05 was
considered statistically significant (**P < 0.01 and ***P < 0.001 vs. PBMCs þ anti-CD3). (C) hAMSCs (passage 1) alone or recovered from
pectin gel dissolution were analyzed for their ability to differentiate toward the osteogenic lineage. hAMSCs were photographed 14 d after
culture in culture media (unstimulated) or differentiation media (stained with Alizarin Red and von Kossa).
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the incubation, the drop in cell viability after 1 h is likely due
to a possible incomplete dissolution of the gel, thus causing an
underestimation of the number of cells, as it was possible to
observe fragments and deposits after the centrifugation step.
The gel environment was able to support cell viability in
agreement with the previous research on different pectin gel
formulations15,36,40,41. Interestingly, the immunological prop-
erties of hAMSCs, that is, their inability to induce a T cell
response and their ability to inhibit the proliferation of
PBMCs activated with anti-CD3, were retained thus indicat-
ing that amniotic cells were able to produce the modulatory
bioactive molecules even after loading into pectin gel. In
addition, the presence of extracellular calcium deposits indi-
cates a mature osteoblast cell function, supporting the hypoth-
esis of the retention of the capability of hAMSCs to
differentiate toward the osteogenic lineage. These aspects
could be considered key features to exploit the potential of
amniotic MSCs toward the development of novel osteochon-
dral regeneration strategies, using a carrier that does not alter
hAMSCs intrinsic properties, such as their immunological and
differentiation properties. The possibility to embed hAMSCs
within a gel is a fundamental achievement to expand the
potential applications of these cells in tissue regeneration.
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